BioCryst Pharmaceuticals (NASDAQ:BCRX) Shares Gap Down – What’s Next?

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)’s stock price gapped down prior to trading on Monday . The stock had previously closed at $8.43, but opened at $7.77. BioCryst Pharmaceuticals shares last traded at $7.15, with a volume of 1,709,944 shares traded.

Analysts Set New Price Targets

BCRX has been the subject of a number of recent research reports. Royal Bank of Canada reissued an “outperform” rating and issued a $10.00 target price on shares of BioCryst Pharmaceuticals in a research note on Tuesday, August 6th. JMP Securities increased their price objective on BioCryst Pharmaceuticals from $15.00 to $16.00 and gave the company a “market outperform” rating in a research note on Tuesday, August 6th. Barclays increased their target price on shares of BioCryst Pharmaceuticals from $6.00 to $7.00 and gave the stock an “equal weight” rating in a report on Tuesday, August 6th. StockNews.com raised BioCryst Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Tuesday, August 6th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $30.00 target price on shares of BioCryst Pharmaceuticals in a research report on Tuesday, August 6th. One analyst has rated the stock with a hold rating and six have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $14.17.

BioCryst Pharmaceuticals Stock Performance

The stock has a 50-day simple moving average of $7.86 and a two-hundred day simple moving average of $6.93. The firm has a market cap of $1.48 billion, a PE ratio of -9.79 and a beta of 1.89.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last issued its earnings results on Monday, August 5th. The biotechnology company reported ($0.06) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.17) by $0.11. The company had revenue of $109.30 million during the quarter, compared to analysts’ expectations of $98.30 million. The company’s revenue for the quarter was up 34.9% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($0.24) EPS. As a group, sell-side analysts anticipate that BioCryst Pharmaceuticals, Inc. will post -0.37 EPS for the current fiscal year.

Institutional Trading of BioCryst Pharmaceuticals

Several large investors have recently modified their holdings of BCRX. CWM LLC boosted its position in BioCryst Pharmaceuticals by 200.0% in the second quarter. CWM LLC now owns 5,658 shares of the biotechnology company’s stock worth $35,000 after purchasing an additional 3,772 shares during the last quarter. Signaturefd LLC increased its holdings in BioCryst Pharmaceuticals by 560.5% during the second quarter. Signaturefd LLC now owns 6,598 shares of the biotechnology company’s stock valued at $41,000 after buying an additional 5,599 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. increased its stake in shares of BioCryst Pharmaceuticals by 21.5% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 7,483 shares of the biotechnology company’s stock worth $57,000 after purchasing an additional 1,322 shares in the last quarter. nVerses Capital LLC bought a new stake in BioCryst Pharmaceuticals during the 2nd quarter worth approximately $63,000. Finally, Seven Eight Capital LP purchased a new stake in BioCryst Pharmaceuticals in the 1st quarter worth $57,000. Institutional investors own 85.88% of the company’s stock.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.